Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CK Life Sciences International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.80%.
CKLSF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.12 Med: 9.25 Max: 18.76
Current: 6.22
During the past 13 years, CK Life Sciences International Holdings's highest ROC (Joel Greenblatt) % was 18.76%. The lowest was 6.12%. And the median was 9.25%.
CKLSF's ROC (Joel Greenblatt) % is ranked better than 81.96% of 1325
companies
in the Biotechnology industry
Industry Median: -297.52
vs CKLSF: 6.22
CK Life Sciences International Holdings (OTCPK:CKLSF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings ROC (Joel Greenblatt) % Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CK Life Sciences International Holdings's ROC (Joel Greenblatt) % falls into.
CK Life Sciences International Holdings ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 11.80% mean?
CK Life Sciences International Holdings (CKLSF) has a ROC (Joel Greenblatt) % of 11.80% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CK Life Sciences International Holdings and its competitors. This is 28% above median its historical median of 9.25. Over the past decade, CK Life Sciences International Holdings' ROC (Joel Greenblatt) % has ranged from 6.12 to 18.76. According to the industry distribution chart, CK Life Sciences International Holdings ranks #239 out of 1325 companies in the Biotechnology industry, placing it in the top 18%.
Is CK Life Sciences International Holdings' ROC (Joel Greenblatt) % too high?
CK Life Sciences International Holdings' current ROC (Joel Greenblatt) % of 11.80% is 28% above median its 10-year median of 9.25. Over the past 10 years, this metric has ranged from a low of 6.12 to a high of 18.76. Based on the distribution chart, CK Life Sciences International Holdings ranks #239 out of 1325 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #239 out of 1325 companies for ROC (Joel Greenblatt) %. This places CK Life Sciences International Holdings in the top 18% of its industry — outperforming the majority of peers. Historically, CK Life Sciences International Holdings' own ROC (Joel Greenblatt) % has ranged from 6.12 to 18.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current ROC (Joel Greenblatt) % is 11.80%, which is 28% above median its own 10-year median of 9.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current ROC (Joel Greenblatt) % of 11.80%. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 11.80%, which is 28% above median its 10-year median of 9.25. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current ROC (Joel Greenblatt) % is 11.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
ROC (Joel Greenblatt) %: 11.80% (28% above median its 10-year median of 9.25)
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
